AMN Healthcare Services (AMN) closed out FY 2025 with Q4 revenue of US$748.2 million and a basic EPS loss of US$0.20, as trailing twelve month figures show revenue of US$2.7 billion and a loss per share of US$2.48 at a share price of US$22.45. Over recent periods the company has seen quarterly revenue move from US$734.7 million in Q4 2024 to US$748.2 million in Q4 2025, while basic EPS has swung between a profit of US$0.76 in Q3 2025 and losses of up to US$3.02 earlier in the year, leaving margins under clear pressure and keeping profitability front and center for investors.

See our full analysis for AMN Healthcare Services.

With the latest numbers on the table, the next step is to see how this path of shifting revenue and EPS lines up with the dominant narratives around AMN and where those stories might need to be reconsidered.

LTM loss of US$95.7 million keeps margins in the red

• Over the last twelve months AMN generated US$2.7b of revenue but reported a loss of US$95.7 million, with trailing EPS at a loss of US$2.48.
• Bears argue that demand softness and pricing pressure will keep profitability under strain, and the recent numbers give them material support:
  • Quarterly results show losses in 3 of the last 4 reported quarters, including a Q2 2025 loss of US$116.2 million and a Q4 2024 loss of US$187.5 million, which aligns with concerns about sustained pressure on net margins.
  • Critics also point to an 11% consolidated revenue drop and a 38% adjusted EBITDA decline referenced in the cautious narrative, which is consistent with the trailing move from US$3.1b of revenue in the LTM to Q3 2024 period to US$2.7b in the latest LTM set.

Investors worried about whether these margin hits are a passing phase or something more persistent may find it useful to see how skeptics frame the downside case in detail 🐻 AMN Healthcare Services Bear Case.

Q3 profit of US$29.3 million sits inside a very choppy year

• Within FY 2025, net income swung from a profit of US$29.3 million in Q3 to losses of US$7.7 million in Q4, US$1.1 million in Q1 and US$116.2 million in Q2, showing a wide range of quarterly outcomes on roughly US$630 million to US$750 million of revenue each period.
• Supporters of the bullish view see these swings as groundwork for a recovery, yet the reported figures create a mixed picture:
  • Consensus narrative mentions rising tech adoption and automation as a path to better margins. However, the latest LTM still shows a US$95.7 million loss and negative net margin, so any efficiency benefits are not yet visible in the aggregate earnings line.
  • At the same time, bulls point to structural healthcare demand and platform rollouts as potential drivers, and the fact that AMN did post a positive US$29.3 million quarter suggests the business can be profitable at current revenue levels if costs and pricing line up more favorably.

If you want to see how optimistic investors connect these patchy results to a possible earnings rebound, it is worth reading the full bullish storyline for context 🐂 AMN Healthcare Services Bull Case.

0.3x P/S and DCF fair value of US$35.94 versus US$22.45 price

• AMN trades on a trailing P/S of 0.3x against peer and US Healthcare averages of 1.1x and 1.2x, while the supplied DCF fair value of US$35.94 sits well above the current share price of US$22.45.
• What stands out for a balanced or consensus style view is the gap between this low sales multiple and the weak trailing earnings profile:
  • On one side, the low P/S and DCF fair value suggest the stock is priced more cheaply than many healthcare peers relative to sales, and the LTM revenue base of US$2.7b is still sizeable despite recent pressure.
  • On the other, the company is unprofitable on a trailing basis and interest payments are not well covered by earnings, so the valuation case rests heavily on future margin improvement rather than support from current net income.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for AMN Healthcare Services on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of caution and optimism leaves you on the fence, take a close look at the numbers yourself, decide quickly what they really imply, and then weigh the 3 key rewards and 1 important warning sign

Explore Alternatives

Choppy earnings, a trailing loss of US$95.7 million and pressure on margins indicate that AMN's recent results involve meaningful uncertainty and execution risk.

If you want ideas that may offer more attractive combinations of price and fundamentals right now, take a few minutes to scan the 51 high quality undervalued stocks and see what stands out for you.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.